Imipenem, cilastatin, and relebactam

(Recarbrio®)

Recarbrio®

Latest News

loading GIF

Drug updated on 4/18/2024

Dosage FormInjection (intravenous; 1.25 g/vial)
Drug ClassPenem antibacterial, renal dehydropeptidase inhibitor, betalactamase inhibitor
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).
  • Indicated in patients 18 years of age and older for the treatment of complicated urinary tract infections, including pyelonephritis (cUTI) in patients who have limited or no alternative treatment options.
  • Indicated in patients 18 years of age and older for the treatment of complicated intra-abdominal infections (cIAI) in patients who have limited or no alternative treatment options.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Imipenem, cilastatin, and relebactam (Recarbrio) are indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), complicated urinary tract infections including pyelonephritis (cUTI), and complicated intra-abdominal infections (cIAI) in adults who have limited or no alternative treatment options.
  • Twenty-two systematic reviews/meta-analyses were analyzed to gather information about Recarbrio’s safety and effectiveness compared to other antimicrobial therapies.
  • Recarbrio has demonstrated effectiveness against gram-negative bacilli resistant to carbapenems, with a pooled resistance prevalence estimation of 14.6%, suggesting its utility where resistance is a concern.
  • The safety profile of Recarbrio was found to be comparable to other antibiotics used in treating cUTIs; it showed similar rates of adverse events but had a higher clinical cure rate and microbiological eradication rate at the test-of-cure stage than traditional antibiotics.
  • Among novel β-lactams evaluated for Pseudomonas aeruginosa infections, such as ceftolozane-tazobactam, ceftazidime-avibactam, and cefiderocol, Recarbrio demonstrated comparable efficacy indicating no inferiority towards these agents.
  • Recarbrio could be effective in treating infections caused by multidrug-resistant organisms, especially among newborns; however, further research is needed to confirm this finding.
  • The pharmacokinetic variability related specifically to ethnicity or pathological conditions did not indicate any need for dosage adjustment based on these characteristics alone, suggesting broad applicability across different demographic groups.
  • In comparison with other combination therapies like ceftazidime/avibactam and ceftolozane/tazobactam, Recarbrio was not considered inferior. These combinations were associated with significant clinical success when dealing with carbapenem-resistant Enterobacterales (CRE) and/or multidrug-resistant Pseudomonas aeruginosa.

Product Monograph / Prescribing Information

Document TitleYearSource
Recarbrio (imipenem, cilastatin, and relebactam) Prescribing Information.2022Merck & Co. Inc., Rahway, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Global mapping of antibiotic resistance rates among clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis.2024Annals of Clinical Microbiology and Antimicrobials
Antimicrobial treatment in invasive infections caused by Gordonia bronchialis: systematic review.2024Frontiers in Medicine
Effectiveness of novel β-lactams for Pseudomonas aeruginosa infection: a systematic review and meta-analysis.2024American Journal of Infection Control
Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: a systematic review and meta-analysis of randomized controlled trials.2023International Journal of Antimicrobial Agents
Global resistance of imipenem/relebactam against gram-negative Bacilli: systematic review and meta-analysis.2023Current Therapeutic Research
Which are the best regimens of broad-spectrum beta-lactam antibiotics in burn patients? a systematic review of evidence from pharmacology studies.2023Antibiotics
Drug resistance and susceptibility of amikacin in children with extended-spectrum beta-lactamase-producing Enterobacterales: a systematic review with meta-analysis.2023Diagnostic Microbiology and Infectious Disease
Clinical efficacy of ertapenem vs. other carbapenems for the treatment of extended-spectrum-β-lactamase-producing Enterobacterales infection: a systematic review and meta-analysis.2023Journal of Global Antimicrobial Resistance
New antimicrobials for the treatment of neonatal sepsis caused by multi-drug-resistant bacteria: a systematic review.2023Antibiotics
A systematic review on antimicrobial pharmacokinetic differences between asian and non-asian adult populations.2023Antibiotics
The status of carbapenem resistance in cystic fibrosis: a systematic review and meta-analysis.2022Yale Journal of Biology
Prevalence of multidrug-resistant and extended-spectrum beta-lactamase-producing shigella species in asia: a systematic review and meta-analysis.2022Antibiotics
Prevalence of multidrug-resistant diarrheagenic escherichia coli in asia: a systematic review and meta-analysis.2022Antibiotics
Global prevalence of colistin resistance in Klebsiella pneumoniae from bloodstream infection: a systematic review and meta-analysis.2022Pathogens
The efficacy and safety of eravacycline compared with current clinically common antibiotics in the treatment of adults with complicated intra-abdominal infections: a Bayesian network meta-analysis.2022Frontiers in Medicine
Evaluating the clinical effectiveness of new beta-lactam/beta-lactamase inhibitor combination antibiotics: a systematic literature review and meta-analysis.2021Antimicrobial Stewardship & Healthcare Epidemiology
Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant gram-negative Bacilli.2021International Journal of Antimicrobial Agents
Is penicillin-nonsusceptible Streptococcus pneumoniae a significant challenge to healthcare system? A systematic review and meta-analysis.2021Scientifica
Carbapenems vs alternative antibiotics for the treatment of complicated urinary tract infection.2020Medicine Open
Carbapenems vs tigecycline for the treatment of complicated intra-abdominal infections: a Bayesian network meta-analysis of randomized clinical trials.2019Medicine Open
Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review.2019Antimicrobial Resistance and Infection Control
Pattern of antibacterial resistance in urinary tract infections: a systematic review and meta-analysis.2019International Journal of Preventive Medicine
Carbapenems vs β-Lactam monotherapy or combination therapy for the treatment of complicated intra-abdominal infections: systematic review and meta-analysis of randomized controlled trials.2019Open Forum Infectious Diseases

Clinical Practice Guidelines